Mirtazapine, an α2 antagonist-type antidepressant reverses pain and lack of morphine analgesia in fibromyalgia-like mouse models

Hiroyuki Neyama1, Naoki Dozono2, Hitoshi Uchida3, and Hiroshi Ueda2

Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

1Current affiliation: RIKEN Center for Biosystems Dynamics Research, Kobe, Japan
2Current affiliation: Department of Molecular Pharmacology, Kyoto University Graduate School of Pharmaceutical Sciences, Kyoto, Japan
3Current affiliation: Department of Cellular Neuropathology, Brain Research Institute, Niigata Univ., Niigata, Japan
Running title: Habenular α2 role in fibromyalgia

Address correspondence to: Hiroshi Ueda, Department of Molecular Pharmacology, Kyoto University Graduate School of Pharmaceutical Sciences, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan.
E-mail: ueda.hiroshi.8e@kyoto-u.ac.jp

Number of text pages: 38
Number of figure and tables: 6 figures and 0 table
Number of references: 71
Words in abstract: 227
Words in introduction: 640
Words in discussion: 1449

Abbreviations: a-CSF: artificial cerebrospinal fluid, ADRA2A: adrenergic α2a receptor, ARRIVE: Animal Research: Reporting In Vivo experiments, DMSO: dimethyl sulfoxide, FM: fibromyalgia, GABA: γ-aminobutyric acid, h: hour, 5-HT: 5-hydroxytryptamine, ICS: intermittent cold stress, IPS: intermittent psychological stress, i.c.v.: intracerebroventricular, i.p.: intraperitoneal, i.t.: intrathecal, LPA1−/−: lysophosphatidic acid receptor 1-deficient, min: minute, mRNA: messenger RNA, MOPr: μ opioid receptor; NMDA: N-methyl-d-aspartate, NSAIDs: non-steroidal anti-inflammatory drugs, NR2A: NMDA receptor subtype 2A, P: Post stress day, qPCR: quantitative polymerase chain reaction, siRNA: small interfering RNA,
SNRI: serotonin and norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor, s: second,

**Brain regions**: ACC: anterior cingulate cortex; LHB: lateral habenula; LH: lateral hypothalamus; LC: locus coeruleus; MHB: medial habenula; MH: medial hypothalamus; MD: mediodorsal thalamus; PBN: parabrachial nucleus; PVN: paraventricular nucleus; PVA: paraventricular thalamic nucleus, anterior part; PAG: periaqueductal gray; RVM: rostroventromedial medulla SNC: substantia nigra pars compacta; VPL: ventral posterolateral nucleus of thalamus; VTA: ventral tegmental area

*Section assignment for table of content*: Behavioral Pharmacology
Abstract

Treatment for fibromyalgia is an unmet medical need; however, its pathogenesis is still poorly understood. In a series of studies, we have demonstrated that some pharmacological treatments reverse generalized chronic pain, but do not affect the lack of morphine analgesia in the intermittent cold stress (ICS)-induced fibromyalgia-like pain model in mice. Here we report that repeated intraperitoneal treatments with mirtazapine, which is presumed to disinhibit 5-HT release and activate 5-HT1 receptor through mechanisms of blocking presynaptic adrenergic α2, postsynaptic 5-HT2 and 5-HT3 receptors, completely reversed the chronic pain for more than 4-5 days after the cessation of treatments. The repeated mirtazapine-treatments also recovered the morphine analgesia after the return of nociceptive threshold to the normal level. The microinjection of siRNA adrenergic α2a receptor (ADRA2A) into the habenula, which showed a selective upregulation of α2 receptor gene expression after ICS, reversed the hyperalgesia, but did not recover the morphine analgesia. However, both reversal of hyperalgesia and recovery of morphine analgesia were observed when siRNA ADRA2A was administered intracerebroventricularly. As the habenular is reported to be involved in the emotion/reward-related pain and hypoalgesia, these results suggest that mirtazapine could attenuate pain and/or augment hypoalgesia by blocking the habenular α2 receptor after ICS. The recovery of morphine analgesia in the ICS model, on the other hand, seems to be mediated through a blockade of α2 receptor in unidentified brain regions.
Significance Statements

This study reports possible mechanisms underlying the complete reversal of hyperalgesia and recovery of morphine analgesia by mirtazapine, a unique antidepressant with adrenergic α2 and serotonergic receptor antagonist properties, in a type of intermittently repeated stress (ICS)-induced fibromyalgia-like pain model. Habenula, a brain region which is related to the control of emotional pain, was found to play key roles in the anti-hyperalgesia, while other brain regions appeared to be involved in the recovery of morphine analgesia in the ICS-model.
Introduction

Since animal models of neuropathic pain were developed (Bennett and Xie, 1988; Ossipov and Porreca, 2013), much effort has been devoted to clarifying the underlying mechanisms towards the end of discovering novel treatments for neuropathic pain by using physiological, anatomical (Basbaum et al., 2009; Devor, 2013) and molecular biological techniques (Ueda, 2006; Ueda, 2008; Costigan et al., 2009; Kuner, 2010; Hill, 2013). Compared to the studies of neuropathic pain, the basic research on chronic widespread pain syndromes, such as fibromyalgia (FM) that is lacking obvious etiology, has been much less advanced, despite 2% of the population suffering from FM (Russell, 2013; Clauw, 2014). As patients with FM are reported to have shown diverse and inconsistent biochemical changes (Russell, 2004), the current information does not seem to be enough for the use in diagnosis and treatment of FM patients. Therefore, basic studies, including pathophysiology and pharmacotherapy using animal models for FM-like syndromes (Sluka and Clauw, 2016) are indispensable.

The pioneering works by Levine and colleagues, and other group have demonstrated that vagotomized animals show widespread pain (Khasar et al., 1998a; Khasar et al., 1998b; Chen et al., 2008). Regarding pharmacological aspects, there is a report that vagotomy-induced hyperalgesia is sensitive to antidepressants, gabapentinoids, and morphine (Furuta et al., 2009). An acid-saline-induced pain model (Sluka et al., 2001), which shows chronic widespread pain, is sensitive to antidepressants, gabapentinoids (Yokoyama et al., 2007; Kim et al., 2009; DeSantana et al., 2013), and morphine (Sluka et al., 2002). In addition to these, a reserpine-induced biogenic amine depletion model and intermittent sound stress model have been reported, and some pathophysiological and pharmacotherapeutic studies have been discussed.
We have also added two different FM-like pain models using intermittent cold and intermittent psychological stress (ICS and IPS, respectively) models (Nishiyori and Ueda, 2008; Ueda and Neyama, 2017). The advantages of our model (ICS and IPS) are observed in the pathophysiologic and pharmacotherapeutic features, which include female-predominance as well as generalized and chronic pain, and lack of morphine analgesia, despite potent anti-nociceptive actions of gabapentinoids and re-uptake inhibitor-type anti-depressants, in agreement with clinical observations (Clauw, 2014; Schrepf et al., 2016). We also found that the mechanisms underlying chronic pain and lack of morphine analgesia are distinct to each other in several studies using ICS model, which demonstrated that repeated administration with pregabalin or donepezil completely reversed the ICS-induced chronic pain lasting several days after the cessation of treatments, while the lack of morphine (i.c.v.) analgesia still remained (Mukae et al., 2015; Neyama et al., 2020). Such discrepant mechanisms were also observed when the study was performed in lysophosphatidic acid receptor 1-deficient (LPA〈sup〉1</sup〉/〈sup>-</sup〉) mice (Neyama et al., 2020), which have been reported to completely block the hyperalgesia in various neuropathic pain models (Inoue et al., 2004; Uchida et al., 2014; Ueda, 2017; Ueda et al., 2018; Ueda et al., 2019).

In recent years, several medicines became available to treat the refractory pain in patients with fibromyalgia (FM). Approved medicines include anti-convulsant pregabalin and antidepressant milnacipran or duloxetine, which have serotonin and norepinephrine reuptake inhibitor activity. Treatment with these medicines have impacted FM patients (Clauw, 2014; Welsch et al., 2018), though the satisfying improvement of quality of life has not been yet reached, due to their side effects (Welsch et al., 2018). The present study is designed to see
whether experimental fibromyalgia-like abnormal pain behaviors in the ICS model could be suppressed by an anti-depressant mirtazapine, whose pharmacological mechanisms underlying anti-depression activity are explained by the disinhibition of 5-HT release by blocking presynaptic α2 receptor, and blockade of post-synaptic excitatory 5-HT2 and 5-HT3 receptors, so that the 5-HT1 receptor-mediated inhibitory signal becomes predominant (Nutt, 1997; Anttila and Leinonen, 2001). In addition, we also discuss the discrepancy of mechanisms underlying chronic pain and lack of morphine analgesia through the pharmacological study using mirtazapine.
Materials and Methods

Animals. Male C57BL/6J mice weighing 20-25 g (6-10 week) were purchased from TEXAM (Nagasaki, Japan). They were kept in a room with a temperature of 21 ± 2°C with free access to a standard laboratory diet and sterile tap water. All experiments were carried out blind. All experiments were performed after approved by the Nagasaki University Animal Care Committee (Number: 1607201325-8) and complied with the recommendations of the International Association for the Study of Pain (Zimmermann, 1983). All study using animals are reported in accordance with the Animal Research: Reporting In Vivo experiments (ARRIVE) guideline (Kilkenny et al., 2010; McGrath et al., 2010; McGrath and Lilley, 2015).

Drug treatments. Drugs were administrated through i.p. (100 μl/10 g body weight), i.c.v. and i.t. (5 μl) routes. Mirtazapine, kindly provided by Meiji Seika Pharma Co., Ltd. (Kanagawa, Japan), was dissolved in saline containing 0.5% methylcellulose for i.p. injection and in the artificial cerebrospinal fluid (α-CSF; 125 mM NaCl, 3.8 mM KCl, 1.2 mM KH2PO4, 26 mM NaHCO3, 10 mM glucose, pH 7.4) containing 0.5% dimethyl sulfoxide (DMSO; Nacalai Tesque, Kyoto, Japan) for i.c.v. injection.

Intermittent cold stress exposure. Mice were exposed to intermittent cold stress (ICS), as described reported (Nishiyori and Ueda, 2008; Neyama et al., 2020). Briefly, mice were placed in a cold room at 4°C overnight (from 4:30 pm to 10:00 am), followed by alternating environmental temperatures between 24 and 4°C every 30 min from 10:00 am to 4:30 pm. This was repeated twice, on consecutive days. On day 3, the mice were returned to their home cage and adapted to a room, at 24°C, for 1 h, before the behavioral studies. We designated the third day following the onset of stress exposure as post-stress exposure day 1 (P1). Mice in the
control group were kept at 24°C for all 3 days (from 4:30 pm on day 1 to 10:00 am on day 3). During the stress period, two mice were kept in each cage (12 x 15 x 10.5 cm), with free access to food and agar in place of water.

**Intermittent psychological stress exposure.** Mice were exposed to intermittent psychological stress by using the communication box (CBX-9M, Muromachi-Kikai, Tokyo, Japan) that has nine compartments (10 cm x 10 cm) divided by transparent plastic walls, as reported previously (Ueda and Neyama, 2017). Electric shocks (0.6 mA), for 1 sec, were randomly produced 120 times during 1 h through the grid floor by a shock generator (CSG-001, Muromachi-Kikai, Tokyo, Japan) with cycler timer (CBX-CT, Muromachi-Kikai, Tokyo, Japan). Floors of compartments located at the center and the 4 corners were uncovered for the foot-shock group, while the remaining 4 compartments were covered with plastic plates for the psychological stress (empathy) group.

**siRNA.** The *in vivo* siRNA delivery using JetSI™ (Polyplus transfection, France) was performed, as previously reported (Neyama et al., 2020). To confirm the brain locus of microinjected siRNA (0.1 μg/μl), 0.2% of Evans blue was added to the final solution. We used siRNA for ADRA2A (NM_007417, SASI_Mm01_00027654) and control siRNA (SIC001), which were purchased from Sigma genosys (Sigma Aldrich).

**Nociception tests.** The threshold of thermal nociception test (Hargreaves test) was evaluated by the latency of paw withdrawal upon thermal stimulus (Hargreaves et al., 1988; Neyama et al., 2020). Mouse were placed in plexiglass cages on top of a glass sheet and habituated 1-3 h there. The thermal stimulator (IITC Inc., Woodland Hills, CA, USA) was positioned under the glass sheet and the focus of the projection bulb was aimed exactly at the
middle of the plantar surface of the animal. A mirror attached to the stimulator permitted visualization of the plantar surface. In this apparatus, the regulator was set at intensity 20, which increases the plantar surface temperature to $45.1 \pm 1.3^\circ C$ (n=10) at 10 s after the start of thermal stimulation (Neyama et al., 2020). A cut-off time of 20 s was set to prevent tissue damage.

In the mechanical nociception test, the stimulus using an electronic von-Frey anesthesiometer with rigid tips (Model 2390, 90 g probe 0.8 mm in outer diameter; IITC Inc.) was delivered to the middle of the plantar surface of the right hind paw (Ueda and Neyama, 2017). The pressure needed to induce a withdrawal response was defined as the mechanical pain threshold.

**Quantitative real-time polymerase chain reaction (qPCR).** Total RNA was prepared from mouse brain tissues, including habenula, mediodorsal thalamus (MD), hippocampus, ventral posterolateral nucleus of thalamus (VPL), amygdala, medial hypothalamus (MH) and lateral hypothalamus (LH; from Bregma -1.46 mm to -1.82 mm), insula cortex (from Bregma 1.7 mm to 1.94 mm), paraventricular thalamic nucleus, anterior part (PVA), paraventricular nucleus (PVN) and somatosensory cortex S1/S2 (from Bregma -0.46 mm to -0.82 mm), anterior cingulate cortex (ACC; from Bregma 0.62 mm to 0.86 mm), periaqueductal gray (PAG; from Bregma -3.28 mm to -3.52 mm), parabrachial nucleus (PBN; from Bregma -4.96 mm to -5.20 mm), locus coeruleus (LC) and rostroventromedial medulla (RVM; from Bregma -5.4 mm to -5.68 mm) (Paxinos and Franklin, 2001) by use of RNeasy Mini Kit (QIAGEN, Tokyo, Japan). To avoid genomic DNA contamination, samples were treated with RNase-Free DNase Kit (QIAGEN). Reverse-transcription was carried out by using PrimeScript RT Reagent Kit (Takara Bio Inc., Kusatsu, Japan), and the PCR amplification of cDNA was performed with Eco Real-
Time PCR System (Illumina, San Diego, CA) and GeneAce SYBR qPCR Mix II (Nippon Gene, Tokyo, Japan). Glyceraldehyde 3-phosphate dehydrogenase (GADPH) was used as an internal control for normalization. Primer sequences used in this study were as follows: GAPDH, 5’-TATGACTCCACTCACGGCAAAT-3’ (forward), 5’-GGGTCTCGCTCTGGGAAGAT-3’ (reverse); ADRA2A, 5’-TAGAACTGACTTTTCTTCGTTTCTC-3’ (forward), 5’-AACATACACGCTCTTCTTCAAGC-3’ (reverse); ADRA2B, 5’-CCATCACCTTTCTCATCCT-3’ (forward), 5’-AACACACGCCAGATTACCA-3’ (reverse); ADRA2C, 5’-ATCTACACTTTGCTTCAATCAGG-3’ (forward), 5’-TCCTTCGAAAGCGGATACGC-3’ (reverse); serotonin 5-HT2a receptor, 5’-CTGCTGGGTTTCCTTGTCAT-3’ (forward), 5’-GTAATCCAGACGCACAGAG-3’ (reverse); serotonin 5-HT3a receptor, 5’-CAATGAGTTTGTGGACGTG-3’ (forward), 5’-TTGTAGTTCTGAACCTCACCT-3’ (reverse); μ opioid receptor (MOPr), 5’-TTCACCCTCTGACCCATGAGT-3’ (forward), 5’-AGAGAACGTTAGGGGTGCAATCT-3’ (reverse); H1, 5’-CAGACCTGATTGTAGGGGCAG-3’ (forward), 5’-CATAGAGAGCCAAAAGAGGCAG-3’ (reverse). In all primer pairs, the presence of a single peak in the melting temperature analysis and linear amplification with increasing number of PCR cycles were validated.

**Stereotaxic in vivo microinjection.** Stereotaxic microinjection into the habenula at P3 after the ICS was performed as previously described (Neyama et al., 2020). The RNA free water solution containing siRNA in 500 nl was injected per site bilaterally to the Habenula in a speed of (500 nl/min) using a glass micropipette made by a PN-30 micropipette puller (NARISHIGE, Tokyo, Japan) under anesthesia with pentobarbital (Nacalai Tesque) 50 mg/kg, i.p. Stereotaxic
coordinates targeted to the habenula were: -1.58 mm − 2.06 mm anterior from the Bregma, ± 0.5 mm − ± 0.3 mm lateral from the midline and 2.5 mm − 2.75 mm ventral from the brain surface at the Bregma according to a mouse brain atlas (Paxinos and Franklin, 2001). Immediately after the behavioral test (P5, 2 day after the microinjection), mouse was sacrificed, the isolated brain dissected, followed by the visual assessment of exact loci of delivered siRNA with Evans blue (0.2%).

**Statistical analysis.** Data were calculated by Graphpad Prism 8.0 software (Graphpad Software, San Diego, CA) using the unpaired t-test, one-way ANOVA with Tukey’s multiple comparisons test or Dunnett’s multiple comparisons test, two-way ANOVA with Tukey’s or Bonferroni’s or Dunnett’s multiple comparisons test. All data are presented as the mean ± standard error of mean (S.E.M.). Differences with p-value of less than 0.05 were considered statistically significant.
Results

Blockade of ICS-induced hyperalgesia by mirtazapine treatment. As previously reported (Nishiyori and Ueda, 2008; Neyama et al., 2020), the potent thermal hyperalgesia was observed at the time point of day 5 (P5) after the intermittent cold stress (ICS) in mice (Fig. 1A). When mirtazapine at 1 mg/kg was given i.p., significant reversal of hyperalgesia with peak effect at 0.5 h was observed, compared with the threshold at ICS Vehicle (Veh)-treatment. The anti-hyperalgesic effect gradually declined and reverted to the Veh-control level at 3 h (Fig. 1A). Mirtazapine has no significant action in control mice. The i.c.v. injection of mirtazapine at 1 μg showed longer anti-hyperalgesic effect, as shown in Fig. 1B. The peak effect was observed at 1 h, still significant at 3 h. On the other hand, there was no significant anti-hyperalgesic effect with the i.t. treatment (Fig. 1C). A dose-related anti-hyperalgesic action of mirtazapine was observed for 0.1-1 mg/kg, i.p. (Fig. 1D) and 0.1 - 1 μg i.c.v. (Fig. 1E), but not at doses up to 1 μg i.t. (Fig. 1F). Similar results were also observed in the mechanical paw pressure test (Supplementary Fig. 1).

Long-lasting reversal of hyperalgesia by repeated mirtazapine treatment. When mirtazapine (1 mg/kg, i.p.) was given every other day from P5 to P13, the thermal nociceptive threshold before each treatment (basal threshold) gradually increased in ICS model, but not in control mice, as shown in Fig. 2A. No mirtazapine-induced acute change in threshold was observed on P11 or P13. The plot of chronological change in the basal threshold showed the complete recovery of thermal and mechanical nociceptive threshold by the time of P13 and for 4 more days after the cessation of mirtazapine-treatments (Fig. 2B and C).

Recovery of morphine analgesia following repeated treatment with mirtazapine. As
previously reported (Nishiyori et al., 2010; Neyama et al., 2020), brain morphine analgesia (0.3 nmol, i.c.v.) in the thermal nociception test was completely lost in ICS mice (Fig. 3A and C). When mirtazapine (1 mg/kg, i.p.) was repeatedly administered from P5 to P13, there was a complete recovery of morphine analgesia. As well as the complete reversal of hyperalgesia at P18, in ICS-mice; no change in the basal nociceptive threshold or morphine analgesia was observed in control mice treated with repeated mirtazapine (Fig. 3D and E), compared to the cases treated with Veh (Fig. 3B and D). Fig. 3F shows the quantitative analyses of repeated mirtazapine-induced reversal of hyperalgesia and recovery of morphine analgesia. Quite similar results were also observed when intermittent psychological stress (IPS)-induced hyperalgesia was evaluated, where the mirtazapine treatments completely reversed the thermal hyperalgesia and recovered morphine analgesia (Fig. 3G).

Upregulation of adrenergic α2a receptor gene expression in the habenula after ICS exposure. The above findings prompted us to test whether ICS exposure could affect the expression levels of mirtazapine target receptors, which include central adrenergic α2, serotonergic 5HT2, 5-HT3 and histaminergic H1 receptors (Nutt, 1997). To this end, we performed qPCR to measure their mRNA levels in 16 pain-related brain regions from control and ICS-treated mice. As shown in Fig. 4, among the brain regions the habenula was the only region showing time-dependent upregulation of α2a receptor mRNA, which started at P1 and lasted through P12 after ICS exposure. On the other hand, we found no substantial increase of α2b or α2c receptor gene expression throughout 16 brain regions and time points, except for a very weak increase of gene expression of α2b in habenula at P5 and PVA at P12, and α2c in PVA at P1 (Supplementary Fig. 3 and 4). Regarding 5-HT2a and 5-HT3a gene expression, there
was transient up-regulation only at the early stage (D2 and/or P1), as shown in Supplementary Fig. 5 and 6. There was no significant change in H1 receptor gene expression throughout all preparations (Supplementary Fig. 7). Similarly, there was no change in μ opioid receptor (MOPr) gene expression except for the case of d2 in amygdala (Supplementary Fig. 8).

**Reversal of hyperalgesia by microinjection of siRNA ADRA2A.** When siRNA for ADRA2A was bilaterally microinjected (0.5 μl each) into habenula at P3 after the ICS (Fig. 5A and C), significant reversal of hyperalgesia was observed at P5, while no significant reversal of hyperalgesia was observed by the microinjection into MD (Fig. 5D). However, no significant analgesic action by i.c.v. morphine at P5 was observed by the siRNA ADRA2A microinjection into habenula (Fig. 5E and F).

**Reversal of hyperalgesia and loss of morphine analgesia by repeated i.c.v. treatments with siRNA ADRA2A.** As shown in Fig. 6A, siRNA ADRA2A was administered (i.c.v.) three times, at P3, 5 and 7, to evaluate for the involvement of ADRA2A in the other brain regions in the hyperalgesia and loss of i.c.v. morphine analgesia. When siRNA ADRA2A was administered every other day (P3, P5 and P7), the reversal of hyperalgesia was observed at P5, P7 and P9, respectively (Fig. 6B) and the significant recovery of morphine analgesia was observed at P7 and P9.
Discussion

In the present study, using the ICS model of FM we found that the systemic administration of mirtazapine has a potent pharmacotherapeutic action, contrasting with our previous study in which several selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) suppressed the ICS-induced pain following intrathecal, but not systemic administration (Nishiyori and Ueda, 2008). In addition, as mirtazapine-induced beneficial effects were observed when given through an i.c.v. route, but not an i.t. route, the mode or site of action of mirtazapine seems to be different from that for SSRIs or SNRIs. In our previous study using the IPS model, duloxetine, a frequently used SNRI for FM patients showed potent anti-hyperalgesia by the i.t. but not i.c.v. route of administration (Ueda and Neyama, 2017). The usefulness of mirtazapine in clinical practice has been reported in FM patients (Miki et al., 2016; Ottman et al., 2018; Welsch et al., 2018).

The first observation in the present study demonstrates that adrenergic α2a receptor expression is upregulated in the habenula, in the ICS model. The upregulation was observed at the pain maintenance stage, P5 to P12, as well as P1, in contrast to the data with other mirtazapine target receptors (α2b, α2c, 5-HT2a, 5-HT3a or H1), which showed no substantial or just transient upregulation. Based on these findings, we knocked down (KD) the ADRA2A receptor by use of siRNA microinjection bilaterally into the habenula and successfully obtained the reversal of the hyperalgesia. Regarding the pain-related role of habenula, there are reports that increased pain sensitivity following the chronic, unpredictable mild stress (a model of depression) was abolished by the electrolytic lesion of LHb (Li et al., 2016), and various types of chronic pain cause an activation of habenula neurons (Elman et al., 2013; Boulos et al., 2017).
These findings suggest that habenula plays roles in the central or emotional pain and analgesia mechanisms during chronic pain (Hikosaka, 2010). Furthermore, it is also reported that both LHb and medial habenula (MHb) projections contribute to the direct and indirect activation of descending serotonergic pain-inhibitory system through raphe nuclei (dorsal raphe and raphe magnus) and PAG, respectively (Shelton et al., 2012; Metzger et al., 2017), suggesting that the intense or repeated stimulation of habenula disinhibits the descending pain inhibitory system.

Regarding possible roles of ADRA2A receptor in habenula, limited information is available, but it is described that high levels of adrenergic α2a receptor (Adra2a) mRNA are detected in the MHb and medial division of LHb of C57BL/6J mouse by in situ hybridization study in the Allen Brain Atlas (https://mouse.brain-map.org/). In addition, there is an interesting report that peripheral damage (superior cervical ganglionectomy) result in increases of norepinephrine levels in habenula (Gottesfeld, 1983), a finding to support the view that noradrenergic system in the habenula is involved in the stress-related pain status (Shelton et al., 2012). In addition to the descending pain inhibitory mechanism, it is interesting to discuss the possibility that mirtazapine may disinhibit the reward-related hypoalgesia through a blockade of habenula-VTA transmission (Taylor et al., 2019), since the habenula projects glutamatergic neurons to VTA (Brinschwitz et al., 2010), where GABAergic interneurons inhibit DA release.

We should also consider the possible actions of mirtazapine on non-neuronal cells expressing ADRA2A (Mori et al., 2002; Morioka et al., 2014; Caraci et al., 2019), and some contribution of other mirtazapine target receptors (5-HT2a, 5-HT3a), showing transient and sporadic upregulation.
The second observation demonstrates that repeated systemic treatments with mirtazapine for 9 days completely reversed the hyperalgesia, an effect that lasted for at least 4 days even after the cessation of mirtazapine treatments (Fig. 3B and C). This type of pain memory inhibition was also observed in the IPS model (Supplementary Fig.2), a model which mimics the pathophysiology (generalized, chronic and female predominant pain) and pharmacotherapy (lack of anti-hyperalgesia by non-steroidal anti-inflammatory Drug (NSAIDs) diclofenac or morphine) of FM patients, as previously reported (Ueda and Neyama, 2017). Similar pain memory inhibition following repeated treatments with drugs was observed with pregabalin and donepezil (Mukae et al., 2015; Mukae et al., 2016). The complete reversal of ICS-induced hyperalgesia by repeated pregabalin treatments (i.c.v.) was observed at 7 days after the cessation of treatments (Mukae et al., 2016). We have observed the inhibition of ICS-hyperalgesia by muscarinic agonist pilocarpine, which is expected to inhibit the dry eyes and dry mouth, a symptom observed in fibromyalgia patients (Mukae et al., 2015). We further observed potent anti-hyperalgesia with a systemic administration of low dose (10 μg/kg i.p.) of donepezil, which has a good central penetration. The complete reversal of hyperalgesia was also observed at 7 days after the cessation of repeated donepezil treatments (Mukae et al., 2015). Thus, it seems that ICS-induced hyperalgesia and its drug-reversibility are attributed to multiple mechanisms in the brain.

The third observation demonstrates that the pharmacotherapeutic feature of mirtazapine is different from other treatments, in terms of re-establishing morphine sensitivity. In our previous studies (Mukae et al., 2015; Neyama et al., 2020), there was no significant analgesia by morphine given after the repeated treatments with pregabalin or donepezil, which completely
reversed the ICS-induced decrease in basal (or pretreatment) threshold to the naïve level. Through these studies, we have speculated that the complete interruption of feed-forward pain loop by repeated treatments with pain inhibitors reverses the pain threshold to the naïve level (or pain memory) even after the treatments. This view reminds us of the fact that repeated treatments with the antagonist of lysophosphatidic acid receptor 1 (LPA₁), which is responsible for the development and maintenance of nerve injury-induced neuropathic pain (Inoue et al., 2004; Ueda et al., 2018). Recently we have reported that LPA₁ is involved in the development and maintenance in several fibromyalgia-like pain models, including IPS and ICS models (Ueda and Neyama, 2017). Indeed, similar findings were also observed with the study using LPA₁−/− mice, which abolish the hyperalgesia, but still lack morphine analgesia in the ICS model (Neyama et al., 2020). However, in the present study using repeated mirtazapine, there was a complete recovery of central morphine analgesia 6 days after the cessation of repeated mirtazapine, which completely reversed ICS-induced hyperalgesia.

An additional interesting finding in the present study is that the KD of adrenergic α2 receptor in the habenula reversed the hyperalgesia, but did not recover the loss of morphine analgesia. As there are reports that opioid μ-receptors in multiple brain loci are involved in the morphine analgesia (Basbaum et al., 1976; Takagi et al., 1977; Fardin et al., 1984; Cohen and Melzack, 1985; Jones and Gebhart, 1988; Taylor et al., 2019), we treated with siRNA for the ADRA2A gene, through the i.c.v. route, which may cover the MOPr-KD at various loci, and successfully obtained the recovery of morphine analgesia in mice, which had been treated with the siRNA. However, the identification of brain loci for the action of siRNA, responsible for recovery of morphine analgesia, remains to be elucidated. Most recently, we have reported that
the lack of morphine analgesia is reversed by the microinjection of siRNA for anti-opioid NMDA NR2A subunit receptor gene into the PAG (Neyama et al., 2020), but the role of ADRA2A in the PAG in terms of anti-opioid systems remains elusive.

Finally, as FM has a female-predominant sex-difference (Clauw, 2014), animal studies using female mice are also necessary. We have previously observed that both male and female mice have similar hyperalgesia in ICS and IPS models, while the hyperalgesia in male, but not female mice is largely attenuated by gonadectomy (Nishiyori and Ueda, 2008; Ueda and Neyama, 2017). Regarding the sexual dimorphism in pain research, there are interesting reports (Sorge et al., 2015; Mapplebeck et al., 2016) that microglia play key roles in the development and maintenance of neuropathic pain in male mice, while their roles are negligible in female mice. Instead in female mice, peripheral T cells are reported to play important roles in fibromyalgia in clinic and experimental neuropathic pain model (Rosen et al., 2017; Banfi et al., 2020). Thus, the studies comprised of another set of experiments for mirtazapine effects using female mice would be the next important subject in combination with the study evaluating the contribution of microglia and T cells.

In conclusion, the present study demonstrated that mirtazapine has beneficial actions in the reversal of hyperalgesia and recovery of morphine analgesia in the ICS- and IPS-induced hyperalgesia. One of mechanisms underlying the reversal of hyperalgesia is the blockade of habenular adrenergic α2 receptor, which is upregulated by ICS exposure. The present findings that the lack of morphine analgesia was reversed by i.c.v. administration of siRNA, but not by habenular microinjection, suggest that ICS-induced hyperalgesia and lack of morphine analgesia are attributed to distinct mechanisms through α2 receptor in terms of brain loci.
Acknowledgments

The authors are grateful to Ryoko Tsukahara, Michiko Nishiyori, Jun Nagai, Takehiro Mukae, Soichiro Kawamoto for the technical helps of realtime PCR and pain behavior tests.

Footnotes

This work was supported in part by Grants-in-Aid for the Platform for Drug Discovery, Informatics, and Structural Life Science [16am0101012j0005] (H. Ueda) from the Japan Agency for Medical Research and Development (AMED), Japan; KAKENHI JP17H01586 (H. Ueda) and JP26253077 (H. Ueda) from JSPS.

Author contributions

Participated in research design: Neyama, and Ueda

Conducted experiments: Neyama, Dozono and Uchida

Performed data analysis: Neyama, Dozono and Uchida

Wrote or contributed to the writing of the manuscript: Uchida and Ueda
References


Elman I, Borsook D and Volkow ND (2013) Pain and suicidality: insights from reward and


Kim SH, Song J, Mun H and Park KU (2009) Effect of the combined use of tramadol and


Nagakura Y, Oe T, Aoki T and Matsuoka N (2009) Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal
Sluka KA, Rohlwing JJ, Bussey RA, Eikenberry SA and Wilken JM (2002) Chronic muscle
pain induced by repeated acid injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists. J Pharmacol Exp Ther 302:1146-1150.


reuptake inhibitors (SNRIs) for fibromyalgia. *Cochrane Database Syst Rev* 2:CD010292.


Figure legends

**Fig. 1. Blockade of ICS-induced hyperalgesia by brain mirtazapine treatment**

(A-C) Time course of nociceptive latency after the administration of mirtazapine (Mir) in the thermal withdrawal test. Results represent the latency (s) at indicated time points after vehicle (Veh) or Mir administration at the time point of P5 in control (Cont) and ICS-mice. The doses of Mir and administration routes were 1 mg/kg, i.p. (A), 1 μg, i.c.v. (B) and 1 μg, i.t. (C), respectively. The number in parenthesis indicates the number of mice in each group. (D-F) Dose-dependent anti-hyperalgesic effects of Mir through different administration routes at P5 in ICS-mice. Results represent the thermal threshold at 0.5, 1 and 0.5 h after Mir i.p., i.c.v. and i.t. administration, respectively. (A-C) **P<0.01, *P<0.05, vs. Cont Veh, ##P<0.01, #P<0.05, vs. ICS Veh, two-way ANOVA followed by Tukey’s multiple comparisons test (A: Interaction F\_9,\_79 = 2.079, P=0.0412; Time: F\_3,\_79 = 0.1549, P=0.9262, Treatment: F\_3,\_79 = 102.6, P<0.0001; B: Interaction F\_12,\_75 = 4.130, P<0.0001, Time F\_4,\_75 = 1.797, P = 0.1383, Treatment F\_3,\_75 = 85.53, P<0.0001; C: F\_9,\_80 = 0.1764, P=0.9960, Time F\_3,\_80 = 0.7303, P=0.5369, Treatment F\_3,\_80 = 116, P<0.0001). (D-F) **P<0.01, *P<0.05, vs. Mir dose 0 (Vehicle) at Cont ##P<0.01, #P<0.05, vs. Mir dose 0 (Vehicle) at ICS P5, one-way ANOVA followed by Tukey’s multiple comparisons test (D: F\_5,\_30 = 15.86, P<0.0001; E: F\_5,\_23 = 18.34, P<0.0001; F: F\_5,\_26 = 11.85, P<0.0001).

**Fig. 2 Long-lasting reversal of hyperalgesia following repeated treatments with Mir in the ICS model**

(A) Time course of change in nociceptive latency induced by Mir (1 mg/kg, i.p.) given at P5, 7, 9, 11 and 13 in the thermal withdrawal test. (B, C) Chronological change of basal thermal
(B) or mechanical (C) nociceptive threshold at time points prior to each Mir administration (P5, 7, 9 and 11), and at P13, 15 and 17. (B, C) **p<0.01, vs. Cont Veh, ##p<0.01, vs. ICS Veh, two-way ANOVA followed by Tukey’s multiple comparisons test (B: Interaction F21, 154=10.33, P<0.0001, Time F7, 154=18.69, P<0.0001, Treatment F3, 154=307.6, P<0.0001; C: Interaction F15, 72=13.88, P<0.0001, Time F5, 72=20.76, P<0.0001, Treatment F3, 72=162.2, P<0.0001).

**Fig. 3 Recovery of morphine analgesia following repeated treatments with Mir.**

(A)Time schedule of Mir treatment, nociceptive and morphine analgesia test in ICS or IPS-mice. (B-E) Time course of nociceptive threshold after the i.c.v. administration of a-CSF (P15) or morphine (P18) in the thermal withdrawal test in Cont (B)- or ICS (C)-mice treated (P5-12) with Veh (B, C) or Mir (D, E). (F) Quantitative comparison of morphine analgesia in Cont or ICS mice pretreated with Veh or Mir. (G) Quantitative comparison of morphine analgesia in Cont or IPS mice pretreated with Veh or Mir. (B, D, E) **p<0.01, *p<0.05, vs. a-CSF, two-way ANOVA followed by Bonferroni’s multiple comparisons test (B: Interaction F6, 42=5.056, P=0.0006, Time F6, 42=4.033, P=0.0028, Treatment F1, 42=21.59, P<0.0001; D: Interaction F6, 42=6.498, P<0.0001, Time F6, 42=3.353, P=0.0086, Treatment F1, 42=40.63, P<0.0001; E: Interaction F6, 42=3.640, P=0.0053, Time F6, 42=4.767, P=0.0009, Treatment F1, 42=32.27, P<0.0001). (F, G) **p<0.01, *p<0.05, vs. morphine dose 0 (a-CSF) at each corresponding column, ##p<0.01, vs. morphine dose 0, Cont, Veh, ††p<0.01, vs. morphine dose 0, ICS/IPS, Veh, unpaired t-test.

**Fig. 4. Upregulation of adrenergic α2a receptor gene expression in the habenula of ICS-**
treated mice

(A-P) Time-course of adrenergic α2a receptor mRNA expression in the brain regions, including Habenula (A), Insula (B), S1 and S2 cortices (C), ACC (D), PVA (E), PVN (F), MD (G), Hippocampus (H), VPL (I), Amygdala (J), MH (K), LH (L), PAG (M), PBN (N), LC (O), RVM (P) after ICS exposure. The mRNA level of adrenergic α2a receptor was quantified by using qPCR and normalized to that of housekeeping gene GAPDH. Data are presented as percentage of each control day and expressed as the means ± S.E.M. from at least 3 mice. (A) **p<0.01, vs. Cont, one-way ANOVA followed by Dunnett’s multiple comparisons test (F4, 42=5.832, P=0.0028).

Fig. 5. Reversal of hyperalgesia by microinjection of siRNA ADRA2A

(A) Time schedule of microinjection, nociceptive and morphine analgesia test. (B) Confirmed sites of siRNA microinjection in habenula area. (C) Decreased ADRA2A gene expression at 2 day (P5) after siRNA microinjection into the habenula of ICS mice. (D) Reversal of thermal hyperalgesia by siRNA ADRA2A into the habenula, but not mediodorsal (MD) thalamus. (E, F) Morphine analgesia in control (E) or ICS (F)-mice after the microinjection into the habenula. (C) **p<0.01, vs. siADRA2A, unpaired t-test. (D) **p<0.01, vs. Cont siADRA2A (-) in habenula, ##p<0.01, vs. ICS P5 siADRA2A (-) in habenula, one-way ANOVA followed by Tukey’s multiple comparisons test (F4, 35=28.81, P<0.0001). (E) **p<0.01, vs. time 0, two-way ANOVA followed by Dunnett’s multiple comparisons test (Interaction F6, 119=0.6948, P=0.6543, Time F6, 119=19.73, P<0.0001, Treatment F1, 119=1.065 P=3.042).
Fig. 6. Reversal of hyperalgesia and loss of morphine analgesia by repeated i.c.v. treatments with siRNA ADRA2A

(A) Time schedule of siRNA ADRA2A injection, nociceptive and morphine analgesia test. (B) Reversal of thermal hyperalgesia by siRNA ADRA2A injection (i.c.v.) in ICS-mice. Nociceptive tests at P3, 5, 7 were performed prior to siRNA injection. (C) Recovery of morphine analgesia at P7 and 9 by repeated siRNA ADRA2A injections (i.c.v.). (B) **p<0.01, vs. siCont at each day, two-way ANOVA followed by Bonferroni’s multiple comparisons test (Interaction F3, 32=3.539, P=0.0255, Time: F3, 32=5.164, P=0.0050, Treatment F1, 32=45.41, P<0.0001). (C) **p<0.01, vs. time 0 at each post day, two-way ANOVA followed by Dunnett’s multiple comparisons test (P5: Interaction F6, 49=0.8573, P=0.5328, Time: F6, 49=0.8649, P=0.5273, Treatment F1, 49=83.82, P<0.0001, siCont n=5, siADRA2A n=4; P7: Interaction F6, 49=4.020, P=0.0024, Time: F6, 49=2.258, P=0.0529, Treatment F1, 49=144.1, P<0.0001, siCont n=5, siADRA2A n=4; P9: Interaction F6, 56=2.141, P=0.0627, Time: F6, 56=2.048, P=0.0743, Treatment F1, 56=151.6, P<0.0001, n=5).
Figures

Fig. 1

Thermal paw withdrawal test

A  ○ Cont Veh (8)  □ Cont Mir 1 mg/kg (4)
    ● ICS Veh (6)  □ ICS Mir 1 mg/kg (6)

B  ○ Cont Veh (8)  □ Cont Mir 1 µg (5)
    ● ICS Veh (4) □ ICS Mir 1 µg (5)

C  ○ Cont Veh (8)  □ Cont Mir 1 µg (6)
    ● ICS Veh (6) □ ICS Mir 1 µg (6)

D  ○ Cont  ● ICS P5

E  ○ Cont  ● ICS P5

F  ○ Cont  ● ICS P5

PWL (s)

Time after i.p. injection (h)

PWL (s) at 0.5 h

Mirtazapine (mg/kg, i.p.)

PWL (s) at 1 h

Mirtazapine (µg, i.c.v.)

PWL (s) at 1 h

Mirtazapine (µg, i.t.)
Fig. 2

A

Cont Veh  Cont Mir 1 mg/kg  ICS Veh  ICS Mir 1 mg/kg

Time after i.p. injection (h)

B

Thermal paw withdrawal test

C

Mechanical paw pressure test

PWL (s)

Post stress (day)
Fig. 3

A

Veh or Mir 1 mg/kg, i.p.  
(P5-P13)  
ICS or IPS  

Thermal test  
a-CSF, i.c.v.  
Thermal test  
morphine  
0.3nmol, i.c.v.  

Post stress (Day)

B

Cont + Veh  
C

ICS + Veh  
D

Cont + Mir 1 mg/kg  
E

ICS + Mir 1 mg/kg

F

Cont  
ICS  
Veh  
Mir  

G

Cont  
IPS  
Veh  
Mir  

0  0.3  0.3  0.3  0.3 
morphine (nmol, i.c.v.)
Fig. 4

Adrenergic α2a receptor gene expression (qPCR)

A. Habenula
B. Insula
C. S1/S2
D. ACC

E. PVA
F. PVN
G. MD
H. Hippocampus

I. VPL
J. Amygdala
K. MH
L. LH

M. PAG
N. PBN
O. LC
P. RVM

Relative abundance

ContD2, P1, P5, P12
Fig. 5

A. siRNA microinjection 0.1 μg/μL

B. Injection site

C. Gene expression of ADR2A in Habenula

D. Cont ICS P5

E. siCont(11) siADRA2A(8)

F. siCont(3) siADRA2A(8)
Fig. 6

A

B

siADRA2A 1 μg/μl, i.c.v.

0 3 4 5 6 7 8 9

ICS Thermal test

Thermal test morphine (0.3 nmol, i.c.v.)

PWL (s)

Post stress (Day)

siCont siADRA2A

** ** **

C

P5 P7 P9

Time after i.c.v. morphine injection (0.3 nmol)